Clinical trial
Family or no, marrow, blood stem cell transplant survival rates equal
Patients who receive a blood stem cell transplant from a donor outside of their family to treat leukemia and other blood diseases are more likely to have graft failure but less likely to experience graft-versus-host disease, a condition caused…
B cell receptor inhibitor causes chronic lymphocytic leukemia remission
A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the America…
Unconventional approach to control HIV epidemics
A new weapon has emerged to prevent HIV infection. Called pre-exposure prophylaxis, or PrEP, it is a strategy of providing medications to at-risk people before they are exposed to the virus. Having shown great promise in recent phase 3 clinical trials,…
Combination of everolimus and exemestane improves survival for women with metastatic breast cancer
San Antonio, TX – In an international Phase III randomized study, everolimus, when combined with the hormonal therapy exemestane, has been shown to dramatically improve progressionSan Antonio, TX – In an international Phase III randomized study, everol…
Mayo Clinic: Obese patients with HER2-positive breast cancer may have worse outcomes
SAN ANTONIO — Obese patients with early-stage HER2-positive breast cancer may have worse outcomes than patients who are normal weight or overweight, Mayo Clinic researchers found in a study presented today at the 2011 CTRC-AACR San Antonio Breast Canc…
Promising MS drug increases neuroprotection
Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical studies for the treatment of relapsing-remitting multiple sclerosis (RRMS). The mechanism of act…